135 related articles for article (PubMed ID: 12820322)
41. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer.
Kuropkat C; Duenne AA; Herz U; Renz H; Werner JA
Neoplasma; 2004; 51(5):375-8. PubMed ID: 15640942
[TBL] [Abstract][Full Text] [Related]
42. [N-acetylneuraminic acid (sialic acid) as a tumor marker in head and neck cancers].
Fischer F; Egg G
HNO; 1990 Oct; 38(10):361-3. PubMed ID: 2283329
[TBL] [Abstract][Full Text] [Related]
43. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma.
Gourin CG; Moretz WH; Weinberger PM; Xia ZS; Liu Z; Terris DJ; Adam BL
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1125-30. PubMed ID: 18025317
[TBL] [Abstract][Full Text] [Related]
44. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study.
van Houten VM; Leemans CR; Kummer JA; Dijkstra J; Kuik DJ; van den Brekel MW; Snow GB; Brakenhoff RH
Clin Cancer Res; 2004 Jun; 10(11):3614-20. PubMed ID: 15173067
[TBL] [Abstract][Full Text] [Related]
45. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma.
Kim CH; Lee JS; Kang SO; Bae JH; Hong SP; Kahng H
Oral Oncol; 2007 Nov; 43(10):1021-5. PubMed ID: 17306605
[TBL] [Abstract][Full Text] [Related]
46. Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability.
Takeda A; Shimada H; Nakajima K; Imaseki H; Suzuki T; Asano T; Ochiai T; Isono K
Eur J Surg; 2001 Jan; 167(1):50-3. PubMed ID: 11213822
[TBL] [Abstract][Full Text] [Related]
47. Serum cystatin C in patients with head and neck carcinoma.
Strojan P; Svetic B; Smid L; Kos J
Clin Chim Acta; 2004 Jun; 344(1-2):155-61. PubMed ID: 15149884
[TBL] [Abstract][Full Text] [Related]
48. p53-positive tumor-distant squamous epithelia of the head and neck reveal selective loss of chromosome 17.
Wolf C; Flechtenmacher C; Dietz A; Weidauer H; Abel U; Maier H; Bosch FX
Laryngoscope; 2004 Apr; 114(4):698-704. PubMed ID: 15064627
[TBL] [Abstract][Full Text] [Related]
49. Serum sialic acid forms as markers for head and neck malignancies.
Bhatavdekar JM; Vora HH; Patel DD
Neoplasma; 1988; 35(4):425-34. PubMed ID: 3185839
[TBL] [Abstract][Full Text] [Related]
50. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy.
Miller FR; Karnad AB; Eng T; Hussey DH; Stan McGuff H; Otto RA
Head Neck; 2008 Jan; 30(1):28-34. PubMed ID: 17657782
[TBL] [Abstract][Full Text] [Related]
51. [The value of serum tumor marker in the diagnosis of lung cancer].
Shi GL; Hu XL; Yue SD; Song CX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):299-301. PubMed ID: 15996327
[TBL] [Abstract][Full Text] [Related]
52. [Detection of p53 protein in advanced head and neck cancer].
Lassaletta L; Brandáriz JA; Benito A; Gómez C; Ballestín C; Hitt R; De La Cruz J; Alvarez-Vicent JJ
Acta Otorrinolaringol Esp; 1999; 50(8):613-8. PubMed ID: 10619896
[TBL] [Abstract][Full Text] [Related]
53. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
[TBL] [Abstract][Full Text] [Related]
54. Tumor markers and lymphatic metastasis in head and neck cancer patients.
Büntzel J; Hornig A; Glatzel M; Micke O; Bruns F; Schäfer U; Fröhlich D
Anticancer Res; 2005; 25(3A):1539-42. PubMed ID: 16033056
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
56. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients.
Jezersek B; Rudolf Z; Novakovic S
Oncol Rep; 2001; 8(1):77-81. PubMed ID: 11115573
[TBL] [Abstract][Full Text] [Related]
57. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
[TBL] [Abstract][Full Text] [Related]
58. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck.
Hoffmann TK; Sonkoly E; Homey B; Scheckenbach K; Gwosdz C; Bas M; Chaker A; Schirlau K; Whiteside TL
Head Neck; 2007 May; 29(5):472-8. PubMed ID: 17111427
[TBL] [Abstract][Full Text] [Related]
59. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Genazzani AR
Anticancer Res; 1998; 18(5B):3763-5. PubMed ID: 9854491
[TBL] [Abstract][Full Text] [Related]
60. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
